Skip to main content
      Ab#0427 #ACR24
      HSS: menopause & systemic rheum disease severity

      1/3 women report worse disease associated w menopa

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Ab#0427 #ACR24 HSS: menopause & systemic rheum disease severity 1/3 women report worse disease associated w menopause Reported more flares, menopausal symptoms Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum @RheumNow
      ❔Can rheum drugs have beneficial effects on cognition?

      💊Possible benefits with MTX and TNFis but certainly an acti

      Mrinalini Dey DrMiniDey

      9 months 4 weeks ago
      ❔Can rheum drugs have beneficial effects on cognition? 💊Possible benefits with MTX and TNFis but certainly an active area of research and more studies needed #ACR24 @RheumNow https://t.co/lCnIRLwNjK
      #ACR24 abst#0430
      - Analyzed 61 SLE pregnancies
      - Higher early gestational Mean Arterial Pressure before 20 Weeks linked

      Bella Mehta bella_mehta

      9 months 4 weeks ago
      #ACR24 abst#0430 - Analyzed 61 SLE pregnancies - Higher early gestational Mean Arterial Pressure before 20 Weeks linked to increased preeclampsia risk - MAP trends at 8-10 and 17-19 weeks showed highest predictive accuracy for risk prediction @RheumNow https://t.co/37mg0WX43v
      A New ACR
      Ab#474 #ACR24
      Hsieh and @NamrataRheum
      Cancer Survival in RA
      Unable to do meta-analysis due to lack of data
      HR for lung

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Ab#474 #ACR24 Hsieh and @NamrataRheum Cancer Survival in RA Unable to do meta-analysis due to lack of data HR for lung cancer in RA 1.04 No clear evid of increased risk, but more data and studies needed Great research project by a high school student (!!) @RheumNow https://t.co/Sfrf2v2UO4
      Global meta-analysis of 61 studies shows TB Preventive treatment (TPT)
      - Reduces active TB risk in rheumatic disease pa

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      Global meta-analysis of 61 studies shows TB Preventive treatment (TPT) - Reduces active TB risk in rheumatic disease patients by 29% (RR: 0.71, CI: 0.57–0.87) - Best outcomes in high TB-burden countries (RR: 0.51) and with isoniazid for >9 months (RR: 0.52). - Dual screening… https://t.co/4P1982ngvL
      Ab#0458 #ACR24
      10 year outcomes of 176 patients with seroneg RA
      32 pts (18%) had change in dx - SpA (11), seropos RA (6)

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Ab#0458 #ACR24 10 year outcomes of 176 patients with seroneg RA 32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1) 40 (23%) had drug-free remission 30 (17%) started b/tsDMARD @RheumNow
      FDA recently approved - fms-like tyrosine kinase 1 (s-Flt1) / placental growth factor (PlGF), for diagnosing preeclampsi

      Bella Mehta bella_mehta

      9 months 4 weeks ago
      FDA recently approved - fms-like tyrosine kinase 1 (s-Flt1) / placental growth factor (PlGF), for diagnosing preeclampsia. sFlt1:PlGF≤38 rules out preeclampsia in SLE sFlt1:PlGF>85 modestly predicts preeclampsia Proteinuria impacts prediction accuracy #ACR24 abst#0809 @RheumNow
      Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No differe

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
      Gender differences in axSpA extend to dse activity assessment tools.

      PREDICT-SpA:
      🔶️BASDAI score performed better

      sheila RHEUMarampa

      9 months 4 weeks ago
      Gender differences in axSpA extend to dse activity assessment tools. PREDICT-SpA: 🔶️BASDAI score performed better in women. 🔶️ ASDAS-CRP homogenous performance on both genders. Consider BASDAI for assessing dse activity in women? @RheumNow #ACR24 abs571 @rheumarhyme https://t.co/rKJXn2EPXa
      👴🏼 Ageing & RMDs at #ACR24

      🧠 14 factors associated with dementia

      ❗️Justin Levenson tells us that if w

      Mrinalini Dey DrMiniDey

      9 months 4 weeks ago
      👴🏼 Ageing & RMDs at #ACR24 🧠 14 factors associated with dementia ❗️Justin Levenson tells us that if we could address all of these, we could reduce dementia risk by 45%! @RheumNow https://t.co/SgC5KMohXy
      Nationwide US study
      -Prevalence of HLH in SLE: 0.13%
      -Higher risk in younger, female, and racial minority patients
      - St

      Bella Mehta bella_mehta

      9 months 4 weeks ago
      Nationwide US study -Prevalence of HLH in SLE: 0.13% -Higher risk in younger, female, and racial minority patients - Strong association with high mortality #ACR24 abst#0619 @RheumNow
      Study on #AI-augmented remote care for SLE:
      - Combined biometric, self-reported, and NLP-extracted data
      - Moderate to st

      Bella Mehta bella_mehta

      9 months 4 weeks ago
      Study on #AI-augmented remote care for SLE: - Combined biometric, self-reported, and NLP-extracted data - Moderate to strong correlations with physician global assessment - Potential to improve remote disease management - but now very accurate for now #ACR24 abst#0635 @RheumNow
      Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB
      ×